A retrospective study assessing the efficacy and immune-related adverse events of Pembrolizumab plus Chemotherapy for advanced Non-small Cell Lung Cancer as first Line therapy in real world setting
Latest Information Update: 09 Mar 2021
At a glance
- Drugs Pembrolizumab (Primary) ; Antineoplastics
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Mar 2021 New trial record
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer